Luxury Ecotourism In Central America, The World’s Most Beautiful Restaurants And More Travel News https://t.co/iXXqHJ3jVU https://t.co/iXXqHJ3jVU ...

Canadians’ boycott of a beloved seaside town in Maine this summer feels more like a heart-wrenching breakup. “The day I come back to Maine will be a happy day for me.” 🔗: https://t.co/OnyFQ9V28r https://t.co/tPkjnHBW8y ...

Luxury Ecotourism In Central America, The World’s Most Beautiful Restaurants And More Travel News https://t.co/oXPqrKle3F ...

Luxury Ecotourism In Central America, The World’s Most Beautiful Restaurants And More Travel Newshttps://t.co/ZprVUi4p0l https://t.co/5QRrEDlYwX ...

Core Insights - Altria Group, Inc. is focusing on its oral nicotine pouch brand on! to enhance its presence in the smoke-free category, achieving over 18% shipment growth in Q1 2025 and increasing its market share to 8.8% [1][7] - The brand on! has captured 17.9% of the nicotine pouch segment, reflecting its strength despite competitive pressures and rising prices [1][7] - Strategic investments, particularly the "It's On!" marketing campaign, have significantly boosted consumer awareness, now exceeding 60% [2] Company Performance - Altria's shipment growth for on! is attributed to effective marketing and the upcoming launch of on! PLUS, targeting a key demographic for expansion [2][3] - The company is well-positioned for future growth through disciplined pricing strategies, brand equity, and planned innovations [3] - Altria's stock has gained 1.5% over the past month, contrasting with a 0.2% decline in the industry [6] Peer Comparison - Philip Morris continues to lead the nicotine pouch market with ZYN, reporting a 63% year-over-year increase in shipments, reaching over 200 million cans in Q1 2025 [4] - Turning Point Brands is also gaining traction with its modern oral products, forecasting nearly 10x year-over-year growth and expanding its sales force [5] Valuation and Earnings Estimates - Altria trades at a forward price-to-earnings ratio of 10.84X, below the industry average of 15.11X [8] - The Zacks Consensus Estimate indicates year-over-year earnings growth of 4.9% for 2025 and 3.3% for 2026 [9]

Canadians’ boycott of a beloved seaside town in Maine this summer feels more like a heart-wrenching breakup https://t.co/ZkywAby3Vm ...

一水 发自 凹非寺 量子位 | 公众号 QbitAI 没错，这就是阿里通义语音团队最新开源的 泛音频生成模型ThinkSound ，主要用于视频配音，主打 让每一帧画面都有专属匹配音效 。 据介绍，它首次将今年大热的 CoT思维链推理 引入了音频领域，解决了传统视频配乐技术往往只能生成单调的背景音，而难以捕捉画面中的 动态细节和空间关系的难题。 AI音效已经进化成这样了吗？？ 打开声音 ，来快速感受一下最新feel： 模拟婴儿哭声，那叫一个高低起伏、荡气回肠，整个节奏和婴儿表情姿态神同步了。 一辆火车由远及近驶来，整个背景音也颇具空间层次感，毫不违和。 甚至连小号这种乐器演奏，声音也能和演奏者的动作一一对上。 就是说，AI现在也能像专业音效师一样逐步思考，通过捕捉视觉细节来生成音画同步的高保真音频。 官方测评显示，ThinkSound在业界知名的音视频数据集VGGSound上，对比6种主流方法 （Seeing&Hearing、V-AURA、FoleyCrafter、 Frieren、V2A-Mapper和MMAudio） ，在核心指标上均实现了显著提升。 | Method | | | | Objective ...

Core Viewpoint - Achieve Life Sciences, Inc. has successfully closed a public offering of 15 million shares of common stock, raising gross proceeds of $45 million to advance the development of cytisinicline for nicotine dependence treatment [1][2]. Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence, with a New Drug Application submitted to the FDA in June 2025 [5]. - The company has completed two Phase 3 studies and an open-label safety study for cytisinicline, and has also conducted a Phase 2 study for vaping cessation [5]. Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, aimed at reducing nicotine cravings and the satisfaction derived from nicotine products [7]. - Approximately 29 million adults in the U.S. smoke combustible cigarettes, and tobacco use is the leading cause of preventable death globally, with over 8 million deaths annually [6]. - There are currently no FDA-approved treatments specifically for nicotine e-cigarette cessation, highlighting a critical need that cytisinicline aims to address [6]. Financial Details - The public offering included 15 million shares at a price of $3.00 per share, along with warrants to purchase up to 16,766,666 additional shares [1]. - Proceeds from the offering will be used for advancing cytisinicline towards FDA marketing approval and for general corporate purposes [2].

Core Insights - Neurocrine Biosciences has initiated a Phase 1 first-in-human clinical study for the investigational compound NBIP-01435, aimed at treating congenital adrenal hyperplasia (CAH) [1][2] - NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist, which may improve androgen control and allow for lower glucocorticoid dosing [3] - The company has a strong commitment to expanding treatment options for CAH, with NBIP-01435 being the first investigational peptide from its biologics pipeline to enter clinical trials [2][4] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [5] - The company has a diverse portfolio that includes FDA-approved treatments for various conditions, including CAH, and a robust pipeline with multiple compounds in mid- to late-phase clinical development [5] - In December 2024, Neurocrine received FDA approval for crinecerfont, marking the first new treatment for CAH in 70 years [3]

图 1 ：指代检测的应用场景实例 最近， IDEA 提出全新解决方案 Rex-Thinker ，首次将人类思维中的 "逻辑推理链" 引入视觉指代任务，让 AI 像人一样分步思考、验证证据，在权威测评中不仅准 确率显著提升，更展现出强大的 "知之为知之" 能力！ Caption ： Rex-Thinker 的思考过程 在日常生活中，我们常通过语言描述寻找特定物体："穿蓝衬衫的人""桌子左边的杯子"。如何让 AI 精准理解这类指令并定位目标，一直是计算机视觉的核心挑 战。现有方法常被两大问题困扰： 决策过程不透明 （"黑箱" 预测）和 拒识能力不足 （对不存在物体输出错误结果）。 Demo论文地址： https://arxiv.org/abs/2506.04034 突破在哪？让 AI 学会 "思考三步走" 传统模型直接输出目标检测框，而 Rex-Thinker 创新性地构建了可解释的推理框架： 1. 规划 （Planning） 拆解语言指令："找到坐在乌龟上的人" → 分解为 "第一步找到乌龟 → 第二步判断每个人是否坐在乌龟上" 2. 验证 （Action ）对每个候选目标（如 "Person 1""Perso ...